Raja Sawaya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Raja Sawaya has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
Hussein Moussa
Department of Neurology American University of Beirut Medical Center Beirut Lebanon
4 shared publicationsNabil El Ayoubi
Department of Neurology American University of Beirut Medical Center Beirut Lebanon
3 shared publicationsRagheb Ismail
Department of Neurology American University of Beirut Medical Center Beirut Lebanon
3 shared publicationsW. Radwan
Department of Neurology, American University Medical Center, Beirut, Lebanon
3 shared publicationsKamar Eid
Department of Neurology American University of Beirut Medical Center Beirut Lebanon
2 shared publicationsM. Hotait
Department of Neurology, American University Medical Center, Beirut, Lebanon
2 shared publications
Latest Publications
- Open Access
- 4 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9)
Spinal Cord Sarcoidosis Treated With Infliximab
Isolated spinal cord lesion could be misinterpreted as a demyelinating disease. The diagnosis of sarcoidosis should be in the differential when other indices for a demyelinating disorder are absent. An inadequate response to intravenous steroid therapy should not rule out spinal sarcoidosis as this report confirms the response to intravenous infliximab.
- 4 September 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (9)
Open AccessSpinal Cord Sarcoidosis Treated With Infliximab
Isolated spinal cord lesion could be misinterpreted as a demyelinating disease. The diagnosis of sarcoidosis should be in the differential when other indices for a demyelinating disorder are absent. An inadequate response to intravenous steroid therapy should not rule out spinal sarcoidosis as this report confirms the response to intravenous infliximab.
- Open Access
- 17 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4) , e72568
Anti‐GD1b Disorder Presenting as Multiple Mononeuropathies
Isolated anti GD1b disorders are quite rare. They usually present with ophthalmoplegia, sensory ataxia, paraproteinemia, and elevated cold agglutinants. The response to immunosuppressant treatment does not seem to be very effective. We report a case of isolated mononeuropathies associated with isolated anti‐GD1b antibodies, without ataxia or paraproteinemia with dramatic response to short course of steroid treatment.
- 17 April 2026
- Published by Wiley in Clinical Case Reports
- Vol. 14 (4) , e72568
Open AccessAnti‐GD1b Disorder Presenting as Multiple Mononeuropathies
Isolated anti GD1b disorders are quite rare. They usually present with ophthalmoplegia, sensory ataxia, paraproteinemia, and elevated cold agglutinants. The response to immunosuppressant treatment does not seem to be very effective. We report a case of isolated mononeuropathies associated with isolated anti‐GD1b antibodies, without ataxia or paraproteinemia with dramatic response to short course of steroid treatment.
- Open Access
- 2 December 2025
- Published by Wiley
Anti-GD1b disorder presenting as multiple mononeuropathies.
- 2 December 2025
- Published by Wiley
Open AccessAnti-GD1b disorder presenting as multiple mononeuropathies.
- Open Access
- 30 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95737
Risk Factors for Developing Critical Illness Polyneuropathy at a Referral Medical Center in Lebanon: A Prospective Cohort Study
Background Critical illness polyneuropathy (CIP) is a common neuromuscular complication in critically ill patients and is associated with increased morbidity, prolonged mechanical ventilation, and delayed recovery. This study aims to identify clinical factors associated with the development or progression of CIP in critically ill patients admitted to a tertiary care center in Lebanon. Methodology This prospective cohort study included 70 adult patients (≥18 years) admitted to the intensive care unit (ICU) at the American University of Beirut Medical Center. Baseline demographics, medical history, and clinical data were collected upon admission. Nerve conduction studies (NCS) were conducted on day zero and repeated on day seven of ICU stay. Hospital course details, new medications, and complications were recorded throughout the observation period. Categorical variables were analyzed using the chi-squared test, while continuous variables were compared using the Mann-Whitney U test. A p-value <0.05 was considered statistically significant. Results Of the 70 patients enrolled, 46 were excluded due to inability to complete the follow-up NCS, primarily because of ICU stays shorter than seven days. The final analysis included 24 patients, among whom nine (37.5%) developed new or progressive CIP by day seven. Among all clinical variables analyzed, only thyroid dysfunction showed a statistically significant association with CIP development (p = 0.026). Notably, 32% of patients with CIP had underlying hypothyroidism or hyperthyroidism. Other commonly suspected factors, including corticosteroid use, beta-blocker therapy, and sepsis, were not statistically significant in this cohort. Conclusions Thyroid dysfunction was significantly associated with the development of CIP in critically ill patients in this study. These findings suggest that thyroid status may play a previously underrecognized role in the pathogenesis of CIP and highlight the potential value of routine thyroid screening in ICU patients. Further research involving larger, multicenter cohorts is warranted to validate these results and investigate the mechanisms linking thyroid dysfunction to neuromuscular complications in critical illness.
- 30 October 2025
- Published by Springer Nature in Cureus
- Vol. 17 (10) , e95737
Open AccessRisk Factors for Developing Critical Illness Polyneuropathy at a Referral Medical Center in Lebanon: A Prospective Cohort Study
Background Critical illness polyneuropathy (CIP) is a common neuromuscular complication in critically ill patients and is associated with increased morbidity, prolonged mechanical ventilation, and delayed recovery. This study aims to identify clinical factors associated with the development or progression of CIP in critically ill patients admitted to a tertiary care center in Lebanon. Methodology This prospective cohort study included 70 adult patients (≥18 years) admitted to the intensive care unit (ICU) at the American University of Beirut Medical Center. Baseline demographics, medical history, and clinical data were collected upon admission. Nerve conduction studies (NCS) were conducted on day zero and repeated on day seven of ICU stay. Hospital course details, new medications, and complications were recorded throughout the observation period. Categorical variables were analyzed using the chi-squared test, while continuous variables were compared using the Mann-Whitney U test. A p-value <0.05 was considered statistically significant. Results Of the 70 patients enrolled, 46 were excluded due to inability to complete the follow-up NCS, primarily because of ICU stays shorter than seven days. The final analysis included 24 patients, among whom nine (37.5%) developed new or progressive CIP by day seven. Among all clinical variables analyzed, only thyroid dysfunction showed a statistically significant association with CIP development (p = 0.026). Notably, 32% of patients with CIP had underlying hypothyroidism or hyperthyroidism. Other commonly suspected factors, including corticosteroid use, beta-blocker therapy, and sepsis, were not statistically significant in this cohort. Conclusions Thyroid dysfunction was significantly associated with the development of CIP in critically ill patients in this study. These findings suggest that thyroid status may play a previously underrecognized role in the pathogenesis of CIP and highlight the potential value of routine thyroid screening in ICU patients. Further research involving larger, multicenter cohorts is warranted to validate these results and investigate the mechanisms linking thyroid dysfunction to neuromuscular complications in critical illness.
- 1 March 2025
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 26 (3) , 116-117
Oculopharyngeal Muscular Dystrophy Responding to Treatment: A Report of 2 Cases
- 1 March 2025
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 26 (3) , 116-117
Oculopharyngeal Muscular Dystrophy Responding to Treatment: A Report of 2 Cases
- Open Access
- 1 November 2021
- Published by Caleo in The Journal of International Advanced Otology
- Vol. 17 (6) , 581-583
Auricular Myoclonus: A Case Report and Literature Review
Auricular myoclonus is an extremely rare disorder that manifests as involuntary semi-rhythmic movements of the auricle. We report the case of a 15-year-old female who presented to our outpatient clinics with bilateral spontaneous, uncontrolled movements of the auricles (auricular myoclonus) that are only briefly suppressible by some facial movements and completely disappear during sleep. Needle electromyography revealed baseline tonic motor unit activity with bursts of higher motor units amplitude in the posterior and superior auricularis muscles. Her symptoms improved with pregabalin intake, however, with incomplete resolution. This paper will review previously reported cases, as well as the different treatment modalities that have been used. Cite this article as: Jabbour CE, Sawaya RA, Zaytoun GM. Auricular myoclonus: A case report and literature review. J Int Adv Otol. 2021;17(6):581-583
- 1 November 2021
- Published by Caleo in The Journal of International Advanced Otology
- Vol. 17 (6) , 581-583
Open AccessAuricular Myoclonus: A Case Report and Literature Review
Auricular myoclonus is an extremely rare disorder that manifests as involuntary semi-rhythmic movements of the auricle. We report the case of a 15-year-old female who presented to our outpatient clinics with bilateral spontaneous, uncontrolled movements of the auricles (auricular myoclonus) that are only briefly suppressible by some facial movements and completely disappear during sleep. Needle electromyography revealed baseline tonic motor unit activity with bursts of higher motor units amplitude in the posterior and superior auricularis muscles. Her symptoms improved with pregabalin intake, however, with incomplete resolution. This paper will review previously reported cases, as well as the different treatment modalities that have been used. Cite this article as: Jabbour CE, Sawaya RA, Zaytoun GM. Auricular myoclonus: A case report and literature review. J Int Adv Otol. 2021;17(6):581-583
- Open Access
- 1 October 2021
- Published by Elsevier in Neurología
- Vol. 36 (8) , 642-643
Should tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
- 1 October 2021
- Published by Elsevier in Neurología
- Vol. 36 (8) , 642-643
Open AccessShould tocilizumab be the first line treatment for neuromyelitis optica together with rituximab?
- 1 June 2021
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 22 (4) , 214-219
Rituximab Treatment for Chronic Idiopathic Axonal Polyneuropathy
Chronic idiopathic axonal polyneuropathy is a disorder of unknown etiology resulting in progressive weakness and sensory disturbances predominantly in the hands and feet. Nerve conduction studies and electromyography confirm axonal damage in the nerves of the upper and lower extremities. The pathology is symmetrical with a distal predilection. Patients usually do not respond to the classical treatment with steroids, intravenous immunoglobulin, plasmapheresis, or immunosuppressant drugs. We describe 2 cases of chronic idiopathic axonal polyneuropathy who received intravenous rituximab as a last resort because of the severity of their symptoms. Both patients showed dramatic improvement in their weakness, muscle atrophy, numbness, and paresthesias only few weeks after the induction dose. Their daily functional activities improved to self-independence.
- 1 June 2021
- Published by Wolters Kluwer Health in Journal of Clinical Neuromuscular Disease
- Vol. 22 (4) , 214-219
Rituximab Treatment for Chronic Idiopathic Axonal Polyneuropathy
Chronic idiopathic axonal polyneuropathy is a disorder of unknown etiology resulting in progressive weakness and sensory disturbances predominantly in the hands and feet. Nerve conduction studies and electromyography confirm axonal damage in the nerves of the upper and lower extremities. The pathology is symmetrical with a distal predilection. Patients usually do not respond to the classical treatment with steroids, intravenous immunoglobulin, plasmapheresis, or immunosuppressant drugs. We describe 2 cases of chronic idiopathic axonal polyneuropathy who received intravenous rituximab as a last resort because of the severity of their symptoms. Both patients showed dramatic improvement in their weakness, muscle atrophy, numbness, and paresthesias only few weeks after the induction dose. Their daily functional activities improved to self-independence.
- 7 May 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (4) , 1121-1122
Petrous apicitis presenting with Horner’s syndrome
- 7 May 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 122 (4) , 1121-1122
Petrous apicitis presenting with Horner’s syndrome
- 5 February 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (5) , 1343-1345
Stiff person syndrome, transverse myelitis and hypothalamitis; three paraneoplastic syndromes associated with occult breast cancer
- 5 February 2021
- Published by Springer Nature in Acta Neurologica Belgica
- Vol. 121 (5) , 1343-1345
Stiff person syndrome, transverse myelitis and hypothalamitis; three paraneoplastic syndromes associated with occult breast cancer